Marshall Wace’s Relay Therapeutics RLAY Stock Holding History

Marshall Wace’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$334K	Sell	17,843 -923,982	-98%	-$13.4M	﹤0.01%	2676
2026 Q1	$9.37M	Buy	+941,825	New	+$8.43M	0.01%	1009
2025 Q3	–	Sell	-51,698	Closed	-$179K	–	3329
2025 Q2	$179K	Buy	+51,698	New	+$154K	﹤0.01%	2476
2025 Q1	–	Sell	-27,768	Closed	-$114K	–	3023
2024 Q4	$114K	Sell	27,768 -1,377,946	-98%	-$7.5M	﹤0.01%	2429
2024 Q3	$9.95M	Buy	1,405,714 +1,129,012	+408%	+$8.43M	0.01%	766
2024 Q2	$1.8M	Buy	+276,702	New	+$1.89M	﹤0.01%	1426
2022 Q1	–	Sell	-2,499	Closed	-$77K	–	3914
2021 Q4	$77K	Sell	2,499 -17,231	-87%	-$545K	﹤0.01%	3452
2021 Q3	$622K	Sell	19,730 -69,101	-78%	-$2.33M	﹤0.01%	2287
2021 Q2	$3.25M	Buy	88,831 +78,729	+779%	+$2.59M	0.01%	1093
2021 Q1	$349K	Buy	+10,102	New	+$438K	﹤0.01%	2076

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Marshall Wace's RLAY Position: Q2 2026 in Review

Marshall Wace reduced its Relay Therapeutics (RLAY) stake by 98% in Q2 2026, selling an estimated $13.4M and leaving 17,843 shares worth $334K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Marshall Wace first reported a position in RLAY in Q1 2021 and has held it in 10 quarters since. The position peaked at $9.95M in Q3 2024. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

Marshall Wace held 17,843 shares of Relay Therapeutics worth $334K as of Q2 2026.
Marshall Wace sold 923,982 Relay Therapeutics shares in Q2 2026, an estimated $13.4M.
Relay Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2676 holding.
Marshall Wace first reported a position in Relay Therapeutics in Q1 2021 and has held it in 10 quarters since.
Marshall Wace's Relay Therapeutics position peaked at $9.95M in Q3 2024.
259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.